2',5-dichloro-2-<3-<<(phthaloylglycyl)amino>methyl>-5-methyl-4H-1,2,4-triazol-4-yl>benzophenone | 64194-72-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2',5-dichloro-2-<3-<<(phthaloylglycyl)amino>methyl>-5-methyl-4H-1,2,4-triazol-4-yl>benzophenone
• 英文别名: N-{4-[4-chloro-2-(2-chloro-benzoyl)-phenyl]-5-methyl-4H-[1,2,4]triazol-3-ylmethyl}-2-phthalimido-acetamide；2',5-dichloro-2-[3-(2-phthalimidoacetamidomethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-benzophenone；N-[[4-[4-chloro-2-(2-chlorobenzoyl)phenyl]-5-methyl-1,2,4-triazol-3-yl]methyl]-2-(1,3-dioxoisoindol-2-yl)acetamide
• CAS: 64194-72-5
• 化学式: C₂₇H₁₉Cl₂N₅O₄
• 分子量: 548.385
• InChiKey: IZYQQDYBBVSJBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2',5-dichloro-2-<3-<<(phthaloylglycyl)amino>methyl>-5-methyl-4H-1,2,4-triazol-4-yl>benzophenone 生成 2',5-二氯-2-(3-甘氨酰氨基甲基-5-甲基-4H-1,2,4-三唑-4-基)二苯甲酮
  参考文献：
  名称：

  Process for producing triazolylbenzophenone derivatives

  摘要：

  公式：##STR1## 其中R代表氢、C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6卤代烷基、--(CH.sub.2).sub.n -X-R.sup.5基团或##STR2##基团，R.sup.5代表氢、C.sub.1 -C.sub.6烷基、C.sub.2 -C.sub.6烯基、C.sub.2 -C.sub.6炔基、C.sub.6 -C.sub.10芳基或C.sub.2 -C.sub.8酰基；X代表硫或氧；n代表0、1、2或3；R.sup.6和R.sup.7各代表氢或C.sub.1 -C.sub.6烷基；或##STR3##代表吡咯烷基、哌啶基、吗啉基或.γ.-甲基哌嗪基；R.sup.1代表氢或卤素；R.sup.2代表卤素、硝基或三氟甲基；R.sup.3代表C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6卤代烷基、C.sub.1 -C.sub.6叠氮基烷基、C.sub.6 -C.sub.10芳基、C.sub.2 -C.sub.8酰基或##STR4##基团；R.sup.4和R.sup.8各代表氢、C.sub.1 -C.sub.6烷基或C.sub.7 -C.sub.10芳基烷基；R.sup.9代表氢或C.sub.1 -C.sub.6烷基；R.sup.10代表氢、C.sub.1 -C.sub.6烷基、C.sub.7 -C.sub.10芳基烷基或C.sub.2 -C.sub.11 .alpha.-氨基酰基；或##STR5##代表邻苯二甲酰亚胺基、吡咯烷基、哌啶基、吗啉基或.γ.-甲基哌嗪基。它们的药物可接受的酸盐，可用作抗焦虑药、镇静剂、催眠剂、抗癫痫药、肌肉松弛剂、抗抑郁药，它们的合成中间体以及它们的制备。

  公开号：

  US04141901A1
• 作为产物：
  描述：

  2-氨基-2',5-二氯二苯酮 在 硫化氢 、 氢溴酸 、 溶剂黄146 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 22.5h， 生成 2',5-dichloro-2-<3-<<(phthaloylglycyl)amino>methyl>-5-methyl-4H-1,2,4-triazol-4-yl>benzophenone
  参考文献：
  名称：

  Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annulated peptidoaminobenzophenones

  摘要：

  A series of the title compounds was prepared via condensation of the 3-(aminomethyl)triazolylbenzophenone (5) with N-protected amino acids, followed by deprotection, amination of the 3-[(chloroacetamido)methyl]triazolylbenzophenone (6a,b), or reduction of the relevant azide derivative (6c). Some of the title compounds were also derived directly from the quinazolines 3 or 4 by acid-induced rearrangement, followed by deprotection. These new amino acid amide derivatives of the triazolylbenzophenones (2) were evaluated for central nervous system (CNS) activity. Members of this class of compounds exhibited a high level of CNS activities. For example, 2',5-dichloro-2-[3-[(glycylamino)methyl]-5-methyl-4H-1,2,4-triazol-4-yl] benzophenone (2c) was as active as triazolam, with an ED50 of 0.58 mg/kg (mice, po), against antifighting activity in the foot shock-induced fighting test. Other triazolylbenzophenone derivatives (2a-f) showed similar pharmacological activities.

  DOI：

  10.1021/jm00354a015

文献信息

• Process for producing triazolylbenzophenone derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US04141901A1

  公开（公告）日：1979-02-27

  Triazolylbenzophenone derivatives of the formula: ##STR1## (wherein R represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 halo-alkyl, the group --(CH.sub.2).sub.n -X-R.sup.5, or the group ##STR2## R.sup.5 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.6 -C.sub.10 aryl, or C.sub.2 -C.sub.8 acyl; X represents sulfur or oxygen; n represents 0, 1, 2, or 3; R.sup.6 and R.sup.7 each represents hydrogen or C.sub.1 -C.sub.6 alkyl; or the group ##STR3## represents pyrrolidino, piperidino, morpholino, or .gamma.-methylpiperazino; R.sup.1 represents hydrogen or halogen; R.sup.2 represents halogen nitro, or trifluoromethyl; R.sup.3 represents C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 halo-alkyl, C.sub.1 -C.sub.6 azido-alkyl, C.sub.6 -C.sub.10 aryl, C.sub.2 -C.sub.8 acyl, or the group ##STR4## R.sup.4 and R.sup.8 each represents hydrogen, C.sub.1 -C.sub.6 alkyl, or C.sub.7 -C.sub.10 aralkyl; R.sup.9 represents hydrogen or C.sub.1 -C.sub.6 alkyl; R.sup.10 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.7 -C.sub.10 aralkyl, or C.sub.2 -C.sub.11 .alpha.-amino-acyl; or the group ##STR5## represents phthalimido, pyrrolidino, piperidino, morpholino, or .gamma.-methylpiperazino) and their pharmaceutically acceptable acid addition salts, useful as anxiolytics, sedatives, hypnotics, anticonvulsants, muscle relaxants, antidepressants, their synthetic intermediates, and their preparation.

  公式：##STR1## 其中R代表氢、C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6卤代烷基、--(CH.sub.2).sub.n -X-R.sup.5基团或##STR2##基团，R.sup.5代表氢、C.sub.1 -C.sub.6烷基、C.sub.2 -C.sub.6烯基、C.sub.2 -C.sub.6炔基、C.sub.6 -C.sub.10芳基或C.sub.2 -C.sub.8酰基；X代表硫或氧；n代表0、1、2或3；R.sup.6和R.sup.7各代表氢或C.sub.1 -C.sub.6烷基；或##STR3##代表吡咯烷基、哌啶基、吗啉基或.γ.-甲基哌嗪基；R.sup.1代表氢或卤素；R.sup.2代表卤素、硝基或三氟甲基；R.sup.3代表C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6卤代烷基、C.sub.1 -C.sub.6叠氮基烷基、C.sub.6 -C.sub.10芳基、C.sub.2 -C.sub.8酰基或##STR4##基团；R.sup.4和R.sup.8各代表氢、C.sub.1 -C.sub.6烷基或C.sub.7 -C.sub.10芳基烷基；R.sup.9代表氢或C.sub.1 -C.sub.6烷基；R.sup.10代表氢、C.sub.1 -C.sub.6烷基、C.sub.7 -C.sub.10芳基烷基或C.sub.2 -C.sub.11 .alpha.-氨基酰基；或##STR5##代表邻苯二甲酰亚胺基、吡咯烷基、哌啶基、吗啉基或.γ.-甲基哌嗪基。它们的药物可接受的酸盐，可用作抗焦虑药、镇静剂、催眠剂、抗癫痫药、肌肉松弛剂、抗抑郁药，它们的合成中间体以及它们的制备。
• HIRAI, KENTARO;FUJISHITA, TOSHIO;ISHIBA, TERUYUKI;SUGIMOTO, HIROHIKO;MATS+, J. MED. CHEM., 1982, 25, N 12, 1466-1473
  作者：HIRAI, KENTARO、FUJISHITA, TOSHIO、ISHIBA, TERUYUKI、SUGIMOTO, HIROHIKO、MATS+

  DOI：——

  日期：——
• US4141901A
  申请人：——

  公开号：US4141901A

  公开（公告）日：1979-02-27
• US4143048A
  申请人：——

  公开号：US4143048A

  公开（公告）日：1979-03-06
• US4147700A
  申请人：——

  公开号：US4147700A

  公开（公告）日：1979-04-03